Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].

Sign on to your account

Questions?
Call Us: 24 x 7 Global Phone Support
Email Us: [email protected]

Bain Capital Community Partnership continues its support of JDRF at the New England Chapter’s Annual Boston Gala

04.23.15

Share this page

Share this page

Bain Capital Community Partnership continues its support of JDRF at the New England Chapter’s Annual Boston Gala

On May 9, the New England Chapter of the JDRF, the leading organization funding type 1 diabetes (T1D) research, will hold its 33rd Annual Gala at the Boston Marriott Copley Place. Bain Capital Community Partnership will once again serve as signature sponsor for the event, which raises funds for JDRF’s crucial research efforts.

Bain Capital’s relationship with JDRF is deep and committed – the firm and its employees have supported JDRF for more than 15 years, and this year alone Bain Capital employees contributed more than $350,000 to the gala. In addition, Sean Doherty, Managing Director and General Counsel of Bain Capital, and Lew Klessel, Managing Director of Bain Capital Private Equity, serve on JDRF New England’s board of directors.

"Bain Capital has been instrumental in shaping JDRF’s strategy and bolstering our fundraising efforts that directly support critical research and outreach activities," said Amy Montalto, Executive Director of JDRF’s New England Chapter.

JDRF is the leading global organization dedicated to funding T1D research. JDRF is devoted to progressively removing the impact of T1D from people’s lives through a continuous flow of life-changing therapies, and, ultimately, a cure. JDRF collaborates with a wide spectrum of partners around the world, currently funding $588 million in scientific research in 17 countries. JDRF’s efforts and leadership extend beyond the research laboratory – the fund’s public advocacy program works with public officials to foster a regulatory environment that allows those suffering from T1D to benefit from potential new therapies and devices as quickly and safely as possible.

Related Content